SCHEMBL18128804

SCHEMBL18128804

CC(C)NC(=O)N1CCC[C@H]1c1ccccc1-c1cncn1CCc1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
FKBP1A P62942 1/20 0.44
IDO1 P14902 3/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2D6 P10635 1/20 0.41
CYP2B6 P20813 1/20 0.41
TP53 P04637 1/20 0.39
CYP11B2 P19099 1/20 0.39
TRPV1 Q8NER1 3/20 0.38
AADAT Q8N5Z0 1/20 0.37
ALDH1A1 P00352 1/20 0.36
OPRM1 P35372 1/20 0.36
TMEM97 Q5BJF2 1/20 0.36
HSP90AA1 P07900 1/20 0.36
HSP90AB1 P08238 1/20 0.36
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
HTR7 P34969 1/20 0.36
HTR6 P50406 1/20 0.36
PPIB P23284 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16719008 1.00 FKBP1A (0.44) FKBP1AIDO1CYP3A4CYP2D6CYP2B6
SCHEMBL20162457 0.89 IDO1 (0.42) IDO1CYP3A4CYP2D6CYP2B6TP53
SCHEMBL16730887 0.89 IDO1 (0.42) IDO1CYP3A4CYP2D6CYP2B6TP53
SCHEMBL16730879 0.88 IDO1 (0.42) FKBP1AIDO1CYP3A4CYP2D6CYP2B6
SCHEMBL16730872 0.86 IDO1 (0.44) IDO1CYP3A4CYP2D6CYP2B6TP53
SCHEMBL16730886 0.85 CYP11B2 (0.46) IDO1CYP3A4CYP2D6CYP2B6CYP11B2
SCHEMBL18128805 0.85 CYP11B2 (0.46) IDO1CYP3A4CYP2D6CYP2B6CYP11B2
SCHEMBL16719039 0.84 FKBP1A (0.42) FKBP1ATRPV1
SCHEMBL16730876 0.84 IDO1 (0.39) IDO1CYP3A4CYP2D6CYP2B6TP53
SCHEMBL16730952 0.83 GRM5 (0.41) IDO1CYP3A4CYP2D6CYP2B6CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9975888-B2 Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug MERCK SHARP & DOHME CORP. (US) 2018-05-22 US disclosed
US-20160297809-A1 ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG MERCK SHARP & DOHME CORP. (US) 2016-10-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160297809-A1 ARYL LINKED IMIDAZOLE AND TRIAZOLE DERIVATIVES AND METHODS OF USE THEREOF FOR IMPROVING THE PHARMACOKINETICS OF A DRUG CYP3A43, CYP3A5, CYP3A4 FKBP1A 641/4885IDO1 71/4885CYP3A4 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.